Two Stable Stocks: Brooks Automation, Inc. (NASDAQ:BRKS), Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)


Brooks Automation, Inc. (NASDAQ:BRKS)

Brooks Automation, Inc. (NASDAQ:BRKS) represented a move of 4.51 percent or $-1.46 per share and closed its previous day trading session at $25.73. 802553 Shares were traded in the last trading session with an Average Volume of 1.12 Million Shares. The stock currently has a Market Capitalization of 1.81 Billion.

Brooks Automation is a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. Their technologies, engineering competencies, and global service capabilities provide customers speed to market, and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, they have been a leading partner to the global semiconductor manufacturing market and through product development initiatives and strategic business acquisitions; they have expanded their reach to meet the needs of customers in the life sciences industry, analytical & research markets, and clean energy solutions.

The stock traded between $20.48 and $34.77 over 1-Year time period showing its price to sales ratio of 2.5. Brooks Automation, Inc. (NASDAQ:BRKS) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $0.73 and 200-Day Simple Moving Average of $-4.25. Its Price to Free Cash Flow is 33.75 and Price to Book of 2.88.

Analyst’s recommended the stock as 1.7 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Brooks Automation, Inc. (NASDAQ:BRKS) reported its Actual EPS of $0.32/share. The analysts offering Earnings Estimates for the company were believing that Brooks Automation, Inc. could bring EPS of $0.29/share. The difference between Actual EPS and Estimated EPS was 0.03 Percent. Thus showing an Earnings Surprise of 10.3 Percent.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

In the last trading session, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) added its value by 3.06% closing at the price of $5.72. The stock currently has market capitalization of 401.94 Million, with average volume of 1.13 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is showing beta of 3.02. This particular value of beta suggests that Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has historically moved 302% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is at $-0.79.

The stock currently has RSI of 48.48. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) topped its 52-week high price of $11.72 on 03/15/17 and 52-Week Low Price of $ 4.60 on 08/09/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.04% and monthly volatility of 5.73% respectively.